悦心健康(002162) - 2025 Q4 - 年度业绩预告

Financial Performance - The company expects a net profit of approximately 7.5 million to 11 million CNY for 2025, marking a turnaround from a loss of 147.12 million CNY in the previous year, representing a growth of 105.10% to 107.48% year-over-year [4]. - The net profit after deducting non-recurring gains and losses is projected to be between -14 million and -10 million CNY, an improvement of 91.65% to 94.03% compared to a loss of 167.59 million CNY last year [4]. - The basic earnings per share is estimated to be between 0.0081 and 0.0119 CNY, recovering from a loss of 0.1595 CNY per share in the previous year [4]. Revenue Expectations - The health business revenue is expected to grow by approximately 15.5% compared to the previous year [6]. - The sales volume of the tile business is projected to decline by approximately 6%, with sales revenue decreasing by about 15.7% year-over-year due to intensified market competition [6]. Asset Management - Asset impairment losses are anticipated to decrease by about 78.76 million CNY compared to last year [6]. Cash Flow - Operating cash flow is expected to be around 87 million CNY, an increase of approximately 4.7 million CNY compared to the previous year [6]. Communication and Forecasting - The company has communicated with the accounting firm regarding the earnings forecast, and there are no discrepancies between the two parties [5]. - The earnings forecast data is preliminary and has not been audited by the accounting firm, with actual performance to be disclosed in the 2025 annual report [7]. - Investors are advised to make cautious decisions and be aware of investment risks due to the preliminary nature of the earnings forecast [7].